Ticker Id

Web url

http://www.ablynx.com/

Contact Email

Short description

Street address

Technologiepark 4, 9052 Ghent

Zip or postal code

Telephone

+32 9 261.06.32

Fax

+32 9 261.06.28

Foundation date

Ceo, president

Number of employees

Long description

Since commencing operations in 2002, Ablynx has generated Nanobody™ leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

Ablynx’s Nanobody™ technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.

Nanotechnology : Zwijnaarde

Ablynx nv